Navigation Links
Liver Cirrhosis-Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Liver Cirrhosis-Pipeline Insights, 2014

http://www.reportlinker.com/p02278626/-Liver-Cirrhosis-Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Liver Cirrhosis-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Liver Cirrhosis. This report provides information on the therapeutic development based on the Liver Cirrhosis dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Liver Cirrhosis
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Liver Cirrhosis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Liver Cirrhosis and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Liver Cirrhosis
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Liver Cirrhosis pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Liver Cirrhosis Overview
- Liver Cirrhosis Pipeline Therapeutics
- Liver Cirrhosis Therapeutics under Development by Companies
- Liver Cirrhosis Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Liver Cirrhosis Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Liver Cirrhosis Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Liver Cirrhosis Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Liver Cirrhosis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Liver Cirrhosis – Discontinued Products
- Liver Cirrhosis – Dormant Products
- Companies Involved in Therapeutics Development for Liver Cirrhosis
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Liver Cirrhosis, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Liver Cirrhosis Assessment by Monotherapy Products
- Liver Cirrhosis Assessment by Combination Products
- Liver Cirrhosis Assessment by Route of Administration
- Liver Cirrhosis Assessment by Stage and Route of Administration
- Liver Cirrhosis Assessment by Molecule Type
- Liver Cirrhosis Assessment by Stage and Molecule Type
- Liver Cirrhosis Therapeutics – Discontinued Products
- Liver Cirrhosis Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Liver Cirrhosis, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Liver Cirrhosis Assessment by Monotherapy Products
- Liver Cirrhosis Assessment by Combination Products
- Liver Cirrhosis Assessment by Route of Administration
- Liver Cirrhosis Assessment by Stage and Route of Administration
- Liver Cirrhosis Assessment by Molecule Type
- Liver Cirrhosis Assessment by Stage and Molecule Type

To order this report: Liver Cirrhosis-Pipeline Insights, 2014
http://www.reportlinker.com/p02278626/-Liver-Cirrhosis-Pipeline-Insights-2014.html
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


 


'/>"/>
SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Liver Diseases-Pipeline Insights, 2014
2. Liver Fibrosis-Pipeline Insights, 2014
3. Liver Transplantation-Pipeline Insights, 2014
4. BioDelivery Sciences to Ring The NASDAQ Stock Market Opening Bell
5. Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan
6. Needle-Free Delivery: Technology and Market Forecast 2014-2024
7. Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org
8. Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis
9. Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients
10. ResMeds New AirSense 10 CPAP and APAP Devices Deliver Superior Patient Comfort and Cost-Saving Efficiency for Healthcare Providers
11. Coloplast Delivers On Ambitious Targets With Solid Interim Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... SHAWNEE, Kan. , April 27, 2016 /PRNewswire/ ... Martabano , a senior from the University of ... winner of the Bayer Excellence in Communication Award ... veterinary schools, which were awarded a total of ... Over the last four years, Bayer has provided ...
(Date:4/27/2016)... 27, 2016 Global  urinalysis ... billion by 2022, according to a new report ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... efficiency and accuracy delivered by the new generation ... novel urinalysis instruments and consumables. For instance, the ...
(Date:4/26/2016)... Hill-Rom Holdings, Inc. (NYSE: HRC ) invites you ... 41 st Annual Health Care Conference on Wednesday, May ... invited to listen to the live discussion via the internet ... http://edge.media-server.com/m/p/mr4uxgas . A recorded replay of the discussion will ... and accessible at the links above until August 1, 2016. ...
Breaking Medicine Technology:
(Date:4/30/2016)... , ... April 30, 2016 , ... Orlando-based Maximized Living ... they go for gold in Rio. Under the care of Maximized Living doctors ... , In an unprecedented showing, Maximized Living is sending the largest contingent of elite ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... notified by the Accreditation Council for Graduate Medical Education (ACGME) that it has ... This is the first accreditation of three residency programs that Memorial is currently ...
(Date:4/29/2016)... ... 2016 , ... Dr. Bernie Siegel, (M.D.) world ... and MIRACLES") addresses touchy topics related to Death live on Dr. Carol ... Bernie Siegel, author of a plethora of essential books-to-read for physicians and all ...
(Date:4/29/2016)... ... , ... Spine Team Texas, a comprehensive spine physician group specializing in the ... has been invited to be a featured speaker at the Texas Society of the ... 30, 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation specialist, ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
Breaking Medicine News(10 mins):